We're back and better than ever. "Like us" on Facebook and enjoy the perks of Student BMJ right at your fingertips at facebook.com/StudentBMJ.

Editorial

The polypill: a magic bullet against cardiovascular disease?

Promising in high risk populations, but perhaps not

  • By: Emma Wallace, Tom Fahey
  • Published: 01 October 2012
  • DOI: 10.1136/sbmj.e6386
  • Cite this as: Student BMJ 2012;20:e6386

Cardiovascular disease remains the leading cause of mortality in developed countries, and has been described as a “global epidemic.”1 In 2003, Wald and Law proposed a new polypill: six drugs combined into one tablet that would work to reduce cardiovascular risk. They proposed the polypill as a way of targeting modifiable cardiovascular risk factors, both for adults with pre-existing cardiovascular disease (secondary prevention) and, more controversially, for adults over 55 years old without cardiovascular disease (primary prevention).2

Wald and Law argued that over 80% of myocardial infarctions and strokes could be prevented if this strategy was adopted. The polypill would contain six ingredients: three blood pressure lowering drugs (a thiazide diuretic, a β blocker, and an angiotension converting enzyme (ACE) inhibitor), a statin, aspirin, and folic acid. Their idea ignited great debate in the medical community regarding its potential to reduce the global burden of cardiovascular disease. The polypill has

To read the rest of this article sign in or complete a FREE registration.

Registration is quick, you only need to do this once and you get FREE access to all the Student BMJ content online.

Go to notice board